Home Featured Page 121

Featured

Latest

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Psychedelic Funding Update: Q1 2026

Bright Minds Biosciences Announces Non-Executive Director Appointment

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of...

PT390 – Vital Psychedelic Conversations

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug...

Numinus Wellness Announces Voting Results From its Annual General and Special...

First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial...

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications...

Psychedelic Research Bulletin: January 2023

PT389 – The Art of Ecstasy: The 90’s British Club Scene...

EDITOR PICKS

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

A Practitioner Statement on the Responsible Development of Ibogaine in the...

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.